Study of alemtuzumab (Campath-1H) monoclonal antibody in patients with relapsed and resistant classical Hodgkin's disease.
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2016
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 30 Jun 2009 Primary endpoint identified as response rate as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 10 Nov 2006 Status change